Featured Research

from universities, journals, and other organizations

Research Conducted At Mattel Children's Hospital Leads To New Treatment For Children With Growth Hormone Deficiency

Date:
December 29, 1999
Source:
University Of California Los Angeles
Summary:
Based on research conducted at Mattel Children's Hospital at UCLA and other research institutions nationwide, the U.S. Food and Drug Administration (FDA) Thursday approved the first long-acting dosage form of recombinant growth hormone for pediatric growth hormone deficiency (GHD).

New Therapy Significantly Reduces Number of Injections Required

Based on research conducted at Mattel Children's Hospital at UCLA and other research institutions nationwide, the U.S. Food and Drug Administration (FDA) Thursday approved the first long-acting dosage form of recombinant growth hormone for pediatric growth hormone deficiency (GHD).

In clinical trials, Nutropin Depot [somatropin (rDNA origin) for injectable suspension] was shown to significantly increase growth rates in children with GHD. The new formulation requires only one or two doses a month (which may require more than one injection per dose), compared with current growth hormone therapies that require multiple doses per week (oftentimes daily).

"Nutropin Depot, a convenient new treatment option, offers my newly diagnosed patients excellent growth potential with 12 or 24 doses a year, instead of 365," said Dr. Mitchell Geffner, UCLA chief of pediatric endocrinology and a principal investigator of the drug at the Mattel Children's Hospital at UCLA.

Nutropin Depot is a long-acting form of Genentech's recombinant human growth hormone (rhGH) using Alkermes' ProLeaseÒ injectable extended-release drug delivery system. The new formulation was designed to reduce the frequency of injections by encapsulating the drug in biodegradable microspheres.

In clinical studies, Nutropin Depot was tested for safety, tolerability and efficacy in children with GHD. Ninety-one patients enrolled at 30 sites in the United States were administered the same total dose of Nutropin Depot -- given once monthly or divided into two equal doses given twice monthly.

The most common adverse effects associated with subcutaneous injections of Nutropin Depot were injection-site reactions (53 percent), which occurred in nearly all patients and included redness; post-injection site pain (47%); and nodules (61%). These side effects all resolved without further intervention. Nutropin Depot should not be used in patients with active tumors or acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or to patients having acute respiratory failure.

Growth hormone deficiency, GHD, is a pituitary disorder resulting in short stature and other physical ailments. It affects approximately 20,000 children nationwide. GHD occurs when the production of growth hormone, secreted by the pituitary gland, is disrupted. Since growth hormone plays a critical role in stimulating body growth and development, and is involved in the production of muscle protein and in the breakdown of fats, a decrease in the hormone affects numerous body processes.


Story Source:

The above story is based on materials provided by University Of California Los Angeles. Note: Materials may be edited for content and length.


Cite This Page:

University Of California Los Angeles. "Research Conducted At Mattel Children's Hospital Leads To New Treatment For Children With Growth Hormone Deficiency." ScienceDaily. ScienceDaily, 29 December 1999. <www.sciencedaily.com/releases/1999/12/991229122829.htm>.
University Of California Los Angeles. (1999, December 29). Research Conducted At Mattel Children's Hospital Leads To New Treatment For Children With Growth Hormone Deficiency. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/1999/12/991229122829.htm
University Of California Los Angeles. "Research Conducted At Mattel Children's Hospital Leads To New Treatment For Children With Growth Hormone Deficiency." ScienceDaily. www.sciencedaily.com/releases/1999/12/991229122829.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) — A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) — The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins